19-11113414-C-G
Variant summary
Our verdict is Uncertain significance. The variant received 5 ACMG points: 5P and 0B. PM5PM2PP3
This summary comes from the ClinGen Evidence Repository: The NM_000527.5(LDLR):c.1323C>G (p.Ile441Met) variant is classified as Uncertain significance - insufficient evidence for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3 and PM5) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PM2 - This variant is absent from gnomAD (gnomAD v2.1.1), so PM2 is Met.PP3 - REVEL = 0.769.It is above 0.75, so PP3 is Met.PM5 - 2 other missense variants in the same codon:- NM_000527.5(LDLR):c.1322T>C (p.Ile441Thr) (ClinVar ID: 251783) - Pathogenic by these guidelines- NM_000527.5(LDLR):c.1322T>A (p.Ile441Asn) (ClinVar ID: 251782) - VUS by these guidelinesThere is 1 variant in the same codon classified as Pathogenic by these guidelines, so PM5 is Met. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10585401/MONDO:0007750/013
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 5 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| LDLR | NM_000527.5 | c.1323C>G | p.Ile441Met | missense_variant | Exon 9 of 18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| LDLR | ENST00000558518.6 | c.1323C>G | p.Ile441Met | missense_variant | Exon 9 of 18 | 1 | NM_000527.5 | ENSP00000454071.1 |
Frequencies
GnomAD3 genomes Cov.: 29
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461698Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 727148 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
Age Distribution
GnomAD4 genome Cov.: 29
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:3Uncertain:1
The NM_000527.5(LDLR):c.1323C>G (p.Ile441Met) variant is classified as Uncertain significance - insufficient evidence for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3 and PM5) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PM2 - This variant is absent from gnomAD (gnomAD v2.1.1), so PM2 is Met. PP3 - REVEL = 0.769. It is above 0.75, so PP3 is Met. PM5 - 2 other missense variants in the same codon: - NM_000527.5(LDLR):c.1322T>C (p.Ile441Thr) (ClinVar ID: 251783) - Pathogenic by these guidelines - NM_000527.5(LDLR):c.1322T>A (p.Ile441Asn) (ClinVar ID: 251782) - VUS by these guidelines There is 1 variant in the same codon classified as Pathogenic by these guidelines, so PM5 is Met.
subject mutated among 2600 FH index cases screened = 1 / previously described in association with FH / Software predictions: Conflicting
Homozygous familial hypercholesterolemia Pathogenic:1
The p.Ile441Met variant (reported as p.Ile420Met) in LDLR has been reported in 1 individual with hypercholesterolemia (Hobbs 1992). This variant is also reported in ClinVar (Variation ID: 251784), and was absent from large population studies. In vitro functional studies using fibroblasts derived from skin cells of the patient with this variant exhibit a significant impact on LDLR receptor activity (Hobbs 1992). In addition, computational prediction tools and conservation analysis suggest that the p.Ile441Met variant may impact the protein. Furthermore, two other variants at the same amino acid position (p.Ile441Asn and p.Ile441Thr) were identified in several patients with hypercholesterolemia and segregated in affected family members, and in vitro functional studies of both variants reveal an impact to receptor function (Benito-Vicente and Hobbs 1992). This data supports a causative role for the p.Ile441Met variant and suggests that changes at this amino acid position are not tolerated. In summary, although additional studies are required to fully establish its clinical significance, the p.Ile441Met variant is likely pathogenic. ACMG/AMP Criteria applied: PM5_Strong, PM2, PP3, PS3_Supporting.
Familial hypercholesterolemia Pathogenic:1
This variant (also known as p.Ile420Met in the mature protein and as FH Roen) is a missense variant located in the first LDLR type B repeat of the EGF precursor homology domain of the LDLR protein. Computational prediction tools and conservation analyses suggest that this variant may have deleterious impact on the protein function. Computational splicing tools suggest that this variant may not impact the RNA splicing. An experimental functional study has shown that patient cells carrying this variant have 5-15% LDLR activity. These cells were from a French individual diagnosed with familial hypercholesterolemia that was apparently compound heterozygous with an unknown second allele (PMID: 1301956). Two other variants at the same amino acid position (p.Ile441Asn and p.Ile441Thr) have been detected in several patients with hypercholesterolemia and segregated in affected family members, and both variants have been shown to be functionally defective (PMID: 1301956, 25741862). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on available evidence, this variant is classified as Likely Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at